



Charles E Dadswell
Vice President, US Intellectual Property



GlaxoSmithKline

February 3, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

GlaxoSmithKline
PO Box 13398
5 Moore Drive
Research Triangle Park, North Carolina
27709-3398
Dir. 919 483 6983
Fax. 919 315 4032
Charles.E.Dadswell@gsk.com
www.gsk.com

Re: United States Patent for *VALVE WITH A VALVE STEM WIPER*
Serial No. 10/031,940 Filed 01/22/2002
Patent No. 6,843,392 B1 Issued 01/18/2005
Attorney Docket No. PG3736USW

Certificate

FEB 13 2006

of Correction

Sir:

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322. This request is made in order to correct the mistakes incurred through the fault of the Patentee, as well as mistakes incurred through the fault of the Patent Office.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith, with an additional copy thereof, and a postal card being enclosed in accordance with the present Patent Office practice.

In accordance with C.F.R. § 1.20(a), the Commissioner is hereby authorized to charge the fees required to Deposit Account No. 07-1392. A Fee Transmittal Form is enclosed herewith, with an additional copy thereof.

Respectfully submitted,

J. Michael Strickland
Registration No. 47115

JMS/jj
Enclosures (5)

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this CERTIFICATE OF CORRECTION and accompanying documents are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: February 3, 2006

02/08/2006 EAREGAY1 00000031 071392 6843392

01 FC:1811

100.00 DA

Johnie Jones
Johnie Jones

FEB 14 2006

Doc Code:

PTO/SB/17 (12-04v2)

Approved for use through 07/31/2006. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 1/18/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

**FEE TRANSMITTAL
for FY 2005**☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) **\$100.00****Complete if Known**

Patent Number	6,843,392 B1
Issue Date	01/18/2005
First Named Inventor	Richard Ian WALKER
Examiner Name	Phillipe Derakshani
Art Unit	3754
Attorney Docket No.	PG3763USW

METHOD OF PAYMENT (check all that apply)
☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Deposit Account Number: 07-1392 Deposit Account Name: GlaxoSmithKline

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid(\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180
Multiple Dependent Claims		
Fee (\$)	Fee Paid (\$)	
Total Claims	Extra Claims	Fee (\$)
- 20 or HP =	x	\$50.00 = \$0.00

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 3 or HP =	x	\$200.00 = \$0.00	

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listing under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	0	/ 50 0 (round up to a whole)	x \$250.00 =	\$0.00


4. OTHER FEE(S)

Non-English specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Request for Certificate of Correction

\$100.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	47,115	Telephone	(919) 483-9024
Name (Print/Type)	J. Michael Strickland	Date	February 3, 2006		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FEB 14 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,843,392 *β1*
APPLICATION NO. : 10/391,940
ISSUE DATE : January 18, 2005
INVENTOR(S) : Richard Ian WALKER

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, Column 6, Line 55 --

Reads: first sealing portion contacts a first of the valve stem,

Should read: first sealing portion contacts a first surface of the valve stem,

Claim 2, Column 7, Line 8 -- should be:

Reads: wiper position adapted to wipe the valve stem

Should read: wiper portion adapted to wipe the valve stem.

Claim 20, Column 7, Line 61 --

Reads: The drug product according to claim 18, where the

Should read: The drug product according to claim 18, wherein the

Claim 20, Column 7, Line 63 --

Reads: albuterol, salmeterol, fluticasone, beclomethasone, salt,

Should read: albuterol, salmeterol, fluticasone, beclomethasone, salts,

Claim 23, Column 8, Line 6 --

Reads: a valve stem having the dispensing pass go and a transfer

Should read: a valve stem having the dispensing passage and a transfer

Claim 32, Column 8, Line 35 --

Reads: propellant is liquified HFA134a or HPA-227 or mixtures

Should read: propellant is liquefied HFA134a or HFA-227 or mixtures

Claim 33, Column 8, Line 39 --

Reads: albuterol, salmeterol fluticasone, beclomethasone, salts,

Should read: albuterol, salmeterol, fluticasone, beclomethasone, salts,

Claim 46, Column 9, Line 47 --

Reads: a valve stem having a dispensing passage, and, said valve

Should read: a valve stem having a dispensing passage, and, contacting said valve

Claim 51, Column 10, Line 25 --

Reads: The valve according to claim 46, wherein the rigid

Should read: The valve according to claim 50, wherein the rigid

Claim 53, Column 10, Line 32 --

Reads: ring comprises an elastomer material.

Should read: ring comprises an elastomeric material.

MAILING ADDRESS OF SENDER (Please do not use customer number)

J. Michael Strickland

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FEB 14 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,843,392 **B1**
APPLICATION NO. : 10/391,940
ISSUE DATE : January 18, 2005
INVENTOR(S) : Richard Ian WALKER

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, Column 6, Line 55 --

Reads: first sealing portion contacts a first of the valve stem,

Should read: first sealing portion contacts a first surface of the valve stem,

Claim 2, Column 7, Line 8 -- should be:

Reads: wiper position adapted to wipe the valve stem

Should read: wiper portion adapted to wipe the valve stem.

Claim 20, Column 7, Line 61 --

Reads: The drug product according to claim 18, where the

Should read: The drug product according to claim 18, wherein the

Claim 20, Column 7, Line 63 --

Reads: albuterol, salmeterol, fluticasone, beclomethasone, salt,

Should read: albuterol, salmeterol, fluticasone, beclomethasone, salts,

Claim 23, Column 8, Line 6 --

Reads: a valve stem having the dispensing pass go and a transfer

Should read: a valve stem having the dispensing passage and a transfer

Claim 32, Column 8, Line 35 --

Reads: propellant is liquified HFA134a or HPA-227 or mixtures

Should read: propellant is liquefied HFA134a or HFA-227 or mixtures

Claim 33, Column 8, Line 39 --

Reads: albuterol, salmeterol fluticasone, beclomethasone, salts,

Should read: albuterol, salmeterol, fluticasone, beclomethasone, salts,

Claim 46, Column 9, Line 47 --

Reads: a valve stem having a dispensing passage, and, said valve

Should read: a valve stem having a dispensing passage, and, contacting said valve

Claim 51, Column 10, Line 25 --

Reads: The valve according to claim 46, wherein the rigid

Should read: The valve according to claim 50, wherein the rigid

Claim 53, Column 10, Line 32 --

Reads: ring comprises an elastomer material.

Should read: ring comprises an elastomeric material.

MAILING ADDRESS OF SENDER (Please do not use customer number)

J. Michael Strickland

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FEB 14 2006